Home / Business and Economy / GeneDx Surges 52% in Q3, Raises Full-Year Guidance
GeneDx Surges 52% in Q3, Raises Full-Year Guidance
17 Nov
Summary
- GeneDx reports $116.7M revenue, up 52% year-over-year
- Exome and genome revenue reaches $98.9M, up 65%
- Adjusted gross margin improves to 74%, net income rises to $14.7M
In a standout performance, GeneDx Holdings Corp. (NASDAQ:WGS) has reported exceptional results for the third quarter of 2025. The company, a specialist in genomic testing with a focus on whole-exome and whole-genome sequencing, saw its revenue soar by 52% year-over-year to $116.7 million. This figure was approximately 12% above Wall Street expectations.
The key driver behind GeneDx's success was a 65% increase in exome and genome revenue, which reached $98.9 million. Test volumes for exome and genome services also grew by a robust 33%. Alongside the top-line growth, the company's profitability expanded, with adjusted gross margin improving to 74% (GAAP 72%) and adjusted net income rising to $14.7 million.
Buoyed by these impressive results, GeneDx has raised its full-year 2025 guidance. The company now expects revenue in the range of $425-$428 million and a 53-55% growth in exome/genome revenue, with an adjusted gross margin of 70-71%.
Guggenheim, a prominent investment firm, has responded to GeneDx's performance by lifting its price target on the stock to $170, maintaining a "Buy" rating. The firm cited the company's continued volume growth, higher average selling prices, and the upward trend in gross margins as key factors behind its bullish stance.
